The Journal of Pain
Volume 6, Issue 10 , Pages 662-672 , October 2005

Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004

  • Theodore J. Cicero

      Affiliations

    • Washington University School of Medicine, St. Louis, Missouri
    • Corresponding Author InformationAddress reprint requests to Theodore J. Cicero, PhD, Washington University School of Medicine, Department of Psychiatry, Campus Box 8134, St. Louis, MO 63110
    • ,
  • James A. Inciardi

      Affiliations

    • University of Delaware, Coral Gables, Florida
    • ,
  • Alvaro Muñoz

      Affiliations

    • The Johns Hopkins University School of Public Health, Baltimore, Maryland

Received 14 January 2005 ,Revised 18 May 2005

References 

  1. Agar MH . The Professional Stranger (An Informal Introduction to Ethnography) . Orlando, FL: Academic Press; 1980;
  2. Brands B , Blake J , Sproule B , Gourlay D , Busto U . Prescription opioid abuse in patients presenting for methadone maintenance treatment . Drug Alcohol Depend . 2004;73:199–207
  3. Breitbart W , Rosenfeld BD , Passik SD . The under-treatment of pain in ambulatory AIDS patients . Pain . 1996;65:239–249
  4. Center for Substance Abuse Treatment, Methadone-Associated Mortality . Report of a National Assessment, May 8-9, 2003. SAMHSA, Publication Number 04-3904 . Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2004;
  5. Cicero TJ, Adams EH, Geller A, Inciardi JA, Muñoz A, Schnoll SH, et al. A post-marketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States . Drug Alcohol Depend . 1999;57:7–22
  6. Cicero TJ, Inciardi JA, Adams E, Geller A, Senay EC, Woody GE, Muñoz A: Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf, May 12, 2005 (Epub ahead of print)
  7. Cicero TJ , Inciardi JA . Diversion and abuse of methadone prescribed for pain management . JAMA . 2005;293:297–298
  8. Cleeland CS , Gonin R , Hatfield A . Pain and its treatment in outpatient with metastatic cancer . N Engl J Med . 1994;330:592–596
  9. Cosman B , Feliciano WC , Wolff M . Pentazocine ulcers . Plast Reconstructive Surg . 1977;59:255–259
  10. Executive Office of the President, Office of National Drug Control Policy (2004) . Pulse Check (Trends in Drug Abuse) . Washington, D.C: ONDCP; 2004;
  11. Faich GA . Adverse-drug reaction monitoring . N Engl J Med . 1986;314:1589–1592
  12. Foley K . The treatment of cancer pain . N Engl J Med . 1985;313:84–95
  13. Fontanarosa PB , Drummond R , DeAngelis CD . Postmarketing surveillance (lack of vigilance, lack of trust) . JAMA . 2004;292:2647–2650
  14. Gossop M , Griffiths P , Powis B , Strang J . Cocaine (patterns of use, route of administration, and severity of dependence) . Br J Psych . 1994;164:660–664
  15. Government Accounting Office (GAO) Report to Congressional Requesters: Prescription Drugs: OxyContin abuse and diversion and efforts to address the problem, Washington, D.C.; GAO-04-0110, 2003
  16. Inciardi JA , Chambers CD . Patterns of pentazocine abuse and addiction . N Y State J Med . 1971;71:1727–1733
  17. Inciardi JA , Goode JL . OxyContin and prescription drug diversion . Consumer Research . 2003;22–25
  18. Joranson DE , Ryan KM , Gilson AM , Dahl JL . Trends in medical use and abuse of opioid analgesics . JAMA . 2000;283:1710–1714
  19. Knisely JS , Campbell ED , Dawson KS , Schnoll SH . Tramadol post-marketing surveillance in health care professionals . Drug Alcohol Depend . 2002;68:15–22
  20. Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MDB, Jonzon B, et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans . J Pharmacol Exp Ther . 2001;299:1056–1065
  21. National Institute on Drug Abuse, Community Epidemiology Work Group . Epidemiologic Trends in Drug Abuse Advance Report. National Institutes of Health, National Institute on Drug Abuse . Bethesda, MD: DHHS; 2002;
  22. Oldendorf WH . Some relationships between addiction and drug delivery to the brain . NIDA Research Monograph . 1992;120:13–25
  23. Passik SD . Same as it ever was? Life after the OxyContin media frenzy . J Pain Symptom Manage . 2003;25:199–201
  24. Perry S , Heindrich G . Management of pain during debridement (a survey of U.S. burn units) . Pain . 1982;13:267–280
  25. Piazza-Hepp TD , Kennedy DL . Reporting of adverse events to MEDWatch . Am J Health Syst Pharm . 1995;2:1436–1439
  26. Portenoy RK . Inadequate outcome of cancer pain treatment (influences on patient and clinician behavior) . In:  Patt RB editors. Problems in Cancer Pain Management . New York, NY: J.B. Lippincott; 1992;p. 119–128
  27. Porter J , Jick H . Addiction rare in patients treated with narcotics . N Engl J Med . 1980;302:123
  28. Rischitelli DG , Karbowicz SH . Safety and efficacy of controlled release oxycodone (a systematic literature review) . Pharmacotherapy . 2002;22:898–904
  29. Roset PN, Farre M, De La Torre R, Mas M, Menoyo E, Hernandez C, et al. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males . Drug Alcohol Depend . 2001;64:285–298
  30. Senay EC . Clinical experience with T’s & B’s . Drug Alcohol Depend . 1985;14:305–311
  31. Strom BL . Potential for conflict of interest in the evaluation of suspected adverse drug reactions (a counterpoint) . JAMA . 2004;292:2643–2646
  32. Substance Abuse and Mental Health Services Administration . Results from the 2002 National Survey on Drug Use and Health (National Findings) . Rockville, MD: Office of Applied Studies; 2003; NHSDA Series: H22, DHSS Publication No. SMA 03-3836,
  33. Substance Abuse and Mental Health Services Administration . Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002 . Rockville, MD: Office of Applied Studies; 2003; NHSDA Series: D-24, DHSS Publication No. SMA 03-3780,
  34. 34. U.S. Dept. of Health and Human Services, Food and Drug Administration May 1999. (Henney Report): Managing the risks from medical product use: creating a risk management framework. Available at: http://www.fda.gov/cder/present/dia-699/opdral-dia/opdral-dia.PPT#4 . Accessed April 5, 2005.
  35. 35. U.S. Dept. of Justice Drug Enforcement Administration Diversion Control Program: August 11, 2004. Prescription Pain Medication: Frequently Asked Questions and Answers for Health Care Professionals and Law Enforcement Personnel. Available at: http://www.deadiversion.usdoj.gov/new.htm. Accessed April 5, 2005.
  36. Ward SE , Goldberg N , Miller-McCauley V . Patient barriers to management of cancer pain . Pain . 1993;52:319–324
  37. Woody GE, Senay EC, Geller A, Adams EH, Inciardi JA, Schnoll S, et al. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride) . Drug Alcohol Depend . 2003;72:163–168
  38. Zacny J , Bigelow G , Compton P , Foley K , Iguchi M , Sannerud C . College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse (position statement) . Drug Alcohol Depend . 2003;69:215–232

 Supported in part by research grants from Purdue Pharma to Washington University (Theodore J. Cicero), University of Delaware (James Inciardi) and Johns Hopkins University (Alvaro Muñoz). The authors were also paid consultants by Purdue Pharma.

PII: S1526-5900(05)00656-5

doi: 10.1016/j.jpain.2005.05.004

The Journal of Pain
Volume 6, Issue 10 , Pages 662-672 , October 2005

Article Tools

* Image Usage & Resolution